205 related articles for article (PubMed ID: 34537760)
1. METTL3-mediated m6A modification of KIF3C-mRNA promotes prostate cancer progression and is negatively regulated by miR-320d.
Ma H; Zhang F; Zhong Q; Hou J
Aging (Albany NY); 2021 Sep; 13(18):22332-22344. PubMed ID: 34537760
[TBL] [Abstract][Full Text] [Related]
2. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP.
Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y
Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729
[TBL] [Abstract][Full Text] [Related]
3. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
4. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
5. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Peng W; Li J; Chen R; Gu Q; Yang P; Qian W; Ji D; Wang Q; Zhang Z; Tang J; Sun Y
J Exp Clin Cancer Res; 2019 Sep; 38(1):393. PubMed ID: 31492150
[TBL] [Abstract][Full Text] [Related]
6. m6A-modified circASXL1 promotes proliferation and migration of ovarian cancer through the miR-320d/RACGAP1 axis.
Tian Q; Mu Q; Liu S; Huang K; Tang Y; Zhang P; Zhao J; Shu C
Carcinogenesis; 2023 Dec; 44(12):859-870. PubMed ID: 37738681
[TBL] [Abstract][Full Text] [Related]
7. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
8. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
Han J; Wang JZ; Yang X; Yu H; Zhou R; Lu HC; Yuan WB; Lu JC; Zhou ZJ; Lu Q; Wei JF; Yang H
Mol Cancer; 2019 Jun; 18(1):110. PubMed ID: 31228940
[TBL] [Abstract][Full Text] [Related]
9. MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m
He H; Wu W; Sun Z; Chai L
Biochem Biophys Res Commun; 2019 Oct; 517(4):581-587. PubMed ID: 31395342
[TBL] [Abstract][Full Text] [Related]
10. METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway.
Ye K; Li L; Wu B; Wang D
Genes Genomics; 2022 Nov; 44(11):1311-1322. PubMed ID: 36074324
[TBL] [Abstract][Full Text] [Related]
11. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Ma XX; Cao ZG; Zhao SL
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
[TBL] [Abstract][Full Text] [Related]
12. Methyltransferase-like 3 (METTL3) mediated N6-methyladenosine (m6A) modifications facilitate mir-25-3p maturation to promote gastrointestinal stromal tumors (GISTs) progression.
Qian K; Xu W; Xia X; Ding J
Genes Genomics; 2022 Dec; 44(12):1519-1530. PubMed ID: 36040683
[TBL] [Abstract][Full Text] [Related]
13. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
14. METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells.
Lin S; Zhu Y; Ji C; Yu W; Zhang C; Tan L; Long M; Luo D; Peng X
J Clin Endocrinol Metab; 2022 Jan; 107(2):474-490. PubMed ID: 34562008
[TBL] [Abstract][Full Text] [Related]
15. METTL3 promotes colorectal cancer metastasis by promoting the maturation of pri-microRNA-196b.
Huang L; Liang D; Zhang Y; Chen X; Chen J; Wen C; Liu H; Yang X; Yang X; Lin S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5095-5108. PubMed ID: 36348020
[TBL] [Abstract][Full Text] [Related]
16. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
17. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Miao W; Chen J; Jia L; Ma J; Song D
Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
[TBL] [Abstract][Full Text] [Related]
18. miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer.
Wu H; Li F; Zhu R
Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):304-316. PubMed ID: 33355622
[TBL] [Abstract][Full Text] [Related]
19. METTL3 promotes choriocarcinoma progression by activating the miR-935/GJA1 pathway in an m6A-dependent manner.
Wang W; Shi J; Zheng L
Am J Reprod Immunol; 2023 Nov; 90(5):e13791. PubMed ID: 37881126
[TBL] [Abstract][Full Text] [Related]
20. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Xu J; Chen Q; Tian K; Liang R; Chen T; Gong A; Mathy NW; Yu T; Chen X
Oncol Rep; 2020 Sep; 44(3):973-986. PubMed ID: 32705223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
